English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Decreased uptake and cellular accumulation of zinc is a common characteristic in cancer of the liver, pancreas and prostate, because these malignant cells are intolerant to the physiological concentrations of zinc. A tea polyphenol, epigallocatechin-3-gallate (EGCG), can enhance the cytotoxicity of zinc ions to cancer, but the application of this is limited by the low stability of EGCG. In this work, we have prepared a material that can simultaneously preserve the EGCG stability and facilitate zinc uptake and accumulation in cancer cells, under conditions that are not harmful to normal cells. Thus, we co-crystallize zinc oxide with EGCG to obtain hybrid EGCG-ZnO crystalline nanoparticles of 16.5 ± 5.3 nm in diameter. The EGCG-ZnO particles effectively kill PC-3 prostate adenocarcinoma cells at concentrations that are not cytotoxic to normal cells, WI-38 human embryonic lung fibroblasts. The EGCG-ZnO particles are two times more cytotoxic against PC-3 cells than the standard ZnO particles. In PC-3 cells, the EGCG-ZnO particles are taken up by endocytosis, followed by lysosomal disruption to release zinc and EGCG into the cytoplasm, finally resulting in nuclear accumulation of zinc.

Epigallocatechin gallate-zinc oxide co-crystalline nanoparticles as an anticancer drug that is non-toxic to normal cells